IFP Advisors Inc Has $5.07 Million Position in Intuitive Surgical, Inc. $ISRG

IFP Advisors Inc grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,751 shares of the medical equipment provider’s stock after purchasing an additional 1,498 shares during the period. IFP Advisors Inc’s holdings in Intuitive Surgical were worth $5,071,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. California State Teachers Retirement System lifted its stake in Intuitive Surgical by 39,531.1% in the 2nd quarter. California State Teachers Retirement System now owns 213,725,958 shares of the medical equipment provider’s stock worth $84,994,539,000 after acquiring an additional 213,186,670 shares in the last quarter. State Street Corp lifted its position in shares of Intuitive Surgical by 1.0% in the fourth quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock worth $8,892,753,000 after purchasing an additional 162,264 shares in the last quarter. Capital World Investors boosted its holdings in shares of Intuitive Surgical by 1.7% during the fourth quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock worth $4,449,491,000 after purchasing an additional 127,526 shares during the period. Norges Bank acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth approximately $2,856,987,000. Finally, Invesco Ltd. grew its position in Intuitive Surgical by 17.4% during the fourth quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock valued at $2,338,350,000 after purchasing an additional 611,268 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Amy L. Ladd sold 400 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $379.00, for a total transaction of $151,600.00. Following the completion of the sale, the director owned 251 shares in the company, valued at approximately $95,129. This represents a 61.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $375.57, for a total value of $28,918.89. Following the transaction, the executive vice president directly owned 881 shares in the company, valued at approximately $330,877.17. This represents a 8.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 11,281 shares of company stock valued at $4,485,432. Corporate insiders own 0.60% of the company’s stock.

Intuitive Surgical Stock Up 0.9%

NASDAQ ISRG opened at $353.24 on Thursday. The stock has a market capitalization of $124.79 billion, a PE ratio of 40.46, a price-to-earnings-growth ratio of 2.64 and a beta of 1.47. The company has a 50 day moving average price of $378.72 and a two-hundred day moving average price of $425.22. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, topping the consensus estimate of $2.48 by $0.32. The company had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. Intuitive Surgical’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.81 EPS. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: A large meta-analysis found that da Vinci robotic-assisted surgery was associated with statistically significant improvements across 13 common benign conditions, including shorter hospital stays and faster returns to work versus laparoscopic and open surgery. The findings support the clinical value of Intuitive’s platform and could help drive hospital adoption. New meta-analysis shows statistically significant improvements in patient outcomes associated with da Vinci surgery
• Positive Sentiment: BTIG reaffirmed its “buy” rating and assigned a $469 price target, implying substantial upside from recent trading levels. Other analyst commentary also remains broadly favorable, although investors may be discounting some recommendations because sell-side ratings tend to be optimistic. BTIG reaffirms buy rating on Intuitive Surgical
• Positive Sentiment: Articles note that ISRG is trading at its cheapest valuation in roughly a decade. Combined with recent revenue growth of about 18% and strong earnings execution, the lower valuation is attracting interest from value-oriented investors. ISRG stock trading at its cheapest in 10 years
• Neutral Sentiment: Intuitive presented at the Wells Fargo Healthcare Conference, keeping investor attention on procedure trends, guidance, competition, and the company’s long-term robotic-surgery opportunity. Intuitive Surgical Wells Fargo Healthcare Conference transcript
• Negative Sentiment: Recent selling pressure has been linked to slower U.S. procedure growth, rising costs, competitive threats, and potential effects from GLP-1 drugs. Investors are also questioning whether the company’s earnings multiple is justified while growth moderates. Why Intuitive Surgical fell more than the broader market
• Negative Sentiment: EVP Mark Brosius reported two sales totaling 69 shares. The transactions were made under a pre-arranged Rule 10b5-1 plan and are small relative to his remaining holdings, limiting their significance; however, broader insider activity has consisted predominantly of sales rather than purchases.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. UBS Group initiated coverage on shares of Intuitive Surgical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $500.00 target price for the company. Mizuho set a $500.00 price target on shares of Intuitive Surgical and gave the company a “neutral” rating in a report on Wednesday, July 15th. Stifel Nicolaus dropped their price target on shares of Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating on the stock in a research note on Friday, July 17th. Raymond James Financial reiterated an “outperform” rating and set a $483.00 price objective (down from $577.00) on shares of Intuitive Surgical in a report on Friday, July 17th. Finally, Robert W. Baird lowered their target price on Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating on the stock in a research note on Friday, July 17th. Twenty-two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $508.68.

About Intuitive Surgical

Intuitive Surgical, Inc is a medical technology company that develops and manufactures robotic-assisted surgical systems and related products. Its technology is designed to support surgeons during minimally invasive procedures by providing enhanced visualization, instrument control and dexterity.

The company’s principal product is the da Vinci Surgical System, which is used across a range of specialties, including general surgery, urology, gynecology, cardiothoracic surgery and other procedures.